TLR9 and atherosclerosis: Our findings were partially substantiated by the reports that the antagonists of TLR7 and TLR9 reduced postinterventional remodeling by preventing neointima formation and accelerated atherosclerosis [10] and chloroquine (a TLR9 inhibitor) induced atheroprotection [11].